Cytokind is the global leader in using UVB light to treat immune disorders and improve survival and the quality of life for patients. The company seeks to provide a value based care model that includes treatment therapies and support to improve longevity across a broad range of disorders. By doing so, Cytokind is disrupting the care model using UVB light in concert with digital therapeutics to create a new value and disease care paradigm to create more patient autonomy and less strain on the hospital care system. The company anticipates that their innovative approach will lead to the development of new nutraceuticals and drugs to improve chronic and acute care. We need to re-imagine our relationship with the sun. Cytokind invites you to follow the light. For more information about Cytokind and our scientific discovery, please visit: www.cytokind.net